Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in a Pediatric Patient with ENS-Associated Hypophosphatemic Rickets
NCT03581591Phase 3Completed
- Sponsor
- Redwood Dermatology Sciences
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of burosumab in hypophosphatemic rickets (HR), sponsored by Redwood Dermatology Sciences. Started Jan 2018; status: completed.
02
Drugs
burosumab
03
Conditions
hypophosphatemic rickets (HR)
Beyond the preview
Go deeper on NCT03581591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581591.